外国搭便车者与美国药品的高昂价格。
Foreign free riders and the high price of US medicines.
作者信息
Light Donald W, Lexchin Joel
机构信息
Department of Psychiatry, University of Medicine and Dentistry of New Jersey, 40E Laurel Road, Stratford, NJ 08084, USA.
出版信息
BMJ. 2005 Oct 22;331(7522):958-60. doi: 10.1136/bmj.331.7522.958.
Abstract
The US government, backed by the pharmaceutical industry, wants to convince Americans that they're paying more for drugs because they're contributing more than their fair share of the costs of research and development. Not so, argue two researchers who have looked at the evidence.
摘要
在美国制药行业的支持下，美国政府试图让美国人相信，他们支付的药价更高是因为他们承担了超过其应分担份额的研发成本。然而，两位研究人员在审视证据后认为并非如此。
相似文献
1
Foreign free riders and the high price of US medicines.外国搭便车者与美国药品的高昂价格。
BMJ. 2005 Oct 22;331(7522):958-60. doi: 10.1136/bmj.331.7522.958.
2
Will lower drug prices jeopardize drug research? A policy fact sheet.降低药品价格会危及药物研发吗？一份政策情况说明书。
Am J Bioeth. 2004 Winter;4(1):W1-4. doi: 10.1162/152651604773067488.
3
Beyond AWP . . . way beyond.超越平均批发价……远远超越。
Value Health. 2010 Jan-Feb;13(1):1. doi: 10.1111/j.1524-4733.2009.00673.x. Epub 2009 Nov 12.
4
The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.药物研发的经济学以及药物疗法在市场中的最终估值。
Clin Pharmacol Ther. 2008 Aug;84(2):263-6. doi: 10.1038/clpt.2008.117. Epub 2008 Jun 11.
5
Getting it right: industry sponsorship and medical research.把握正确方向：行业赞助与医学研究
CMAJ. 2003 May 13;168(10):1267-9.
6
Pharmaceutical research: cost savings through innovation.药物研究：通过创新实现成本节约。
AAPPO J. 1993 Oct;3(5):28-36.
7
US doctors earn speaking and consulting fees from drug companies that sponsor their research.
BMJ. 2014 Mar 27;348:g2410. doi: 10.1136/bmj.g2410.
8
Drug discovery.药物发现
Science. 2004 Mar 19;303(5665):1729. doi: 10.1126/science.303.5665.1729.
9
The pharmaceutical industry--prices and progress.制药行业——价格与进展。
N Engl J Med. 2004 Aug 26;351(9):927-32. doi: 10.1056/NEJMhpr040117.
10
Has Big Pharma hijacked the European health research budget?大型制药公司是否操控了欧洲的健康研究预算？
Lancet. 2014 Apr 5;383(9924):1210. doi: 10.1016/S0140-6736(14)60232-4. Epub 2014 Mar 20.
引用本文的文献
1
Prevalence of pharmaceutical industry conspiracy theories among the polish population.波兰民众中制药行业阴谋论的流行程度。
Sci Rep. 2025 Mar 29;15(1):10857. doi: 10.1038/s41598-025-95626-2.
2
Suicide Mortality Risk among Patients with Lung Cancer-A Systematic Review and Meta-Analysis.肺癌患者自杀死亡率的系统评价和荟萃分析。
Int J Environ Res Public Health. 2023 Feb 25;20(5):4146. doi: 10.3390/ijerph20054146.
3
The Challenge of High Drug Prices in America: Cost Disclosure in Direct-to-Consumer Advertising May Offer a Solution.美国高药价的挑战：直接面向消费者的广告中的成本披露或许能提供一个解决方案。
Am Health Drug Benefits. 2019 Sep;12(5):254-255.
4
Public sector financial support for late stage discovery of new drugs in the United States: cohort study.美国公共部门对新药后期发现的财政支持：队列研究。
BMJ. 2019 Oct 23;367:l5766. doi: 10.1136/bmj.l5766.
5
Patients not patents: Drug research and development as a public enterprise.患者而非专利：作为公共事业的药物研发
Eur J Clin Invest. 2018 Feb;48(2). doi: 10.1111/eci.12875. Epub 2018 Jan 5.
6
Affordability of medicines in the European Union.欧盟药品的可负担性。
PLoS One. 2017 Feb 27;12(2):e0172753. doi: 10.1371/journal.pone.0172753. eCollection 2017.
7
Views on the ethical struggle for universal, high quality, affordable health care and its relevance for gerontology.关于为实现全民、高质量、可负担的医疗保健而进行的伦理斗争及其与老年医学的相关性的观点。
Exp Gerontol. 2017 Jan;87(Pt B):182-189. doi: 10.1016/j.exger.2016.04.010. Epub 2016 Apr 19.
8
Health policy: Putting a price on cancer.卫生政策：为癌症定价。
Nat Rev Clin Oncol. 2016 Mar;13(3):137-8. doi: 10.1038/nrclinonc.2016.12. Epub 2016 Feb 9.
9
Effectiveness, safety and costs of orphan drugs: an evidence-based review.罕见病药物的有效性、安全性及成本：一项基于证据的综述。
BMJ Open. 2015 Jun 24;5(6):e007199. doi: 10.1136/bmjopen-2014-007199.
10
US pharmaceutical innovation in an international context.美国制药业的国际创新。
Am J Public Health. 2010 Jun;100(6):1075-80. doi: 10.2105/AJPH.2009.178491. Epub 2010 Apr 19.
本文引用的文献
1
Pricing medicines: theory and practice, challenges and opportunities.药品定价：理论与实践、挑战与机遇。
Nat Rev Drug Discov. 2005 Feb;4(2):121-30. doi: 10.1038/nrd1633.
2
Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.美国老年人使用的品牌处方药制造商价格趋势——2004年第一季度更新
Issue Brief (Public Policy Inst (Am Assoc Retired Pers)). 2004 Jun(IB69):1-12, 1-2.
3
Industrial interests versus public health: the gap is growing.产业利益与公众健康：差距正在扩大。
Prescrire Int. 2004 Apr;13(70):71-6.
4
No exit and the organization of voice in biotechnology and pharmaceuticals.
J Health Polit Policy Law. 2003 Apr-Jun;28(2-3):473-507. doi: 10.1215/03616878-28-2-3-473.
Zotero 插件